*Title:* **Designer T-cells and T-cell receptors for customised cancer immunotherapies**

Mateusz Legut[a] and Andrew K. Sewell[a]

[a]Division of Infection and Immunity, Cardiff University School of Medicine, Henry Wellcome Building, University Hospital Wales, Cardiff CF14 4XN, Wales, UK

*Correspondence:* sewellak@cardiff.ac.uk

*Declarations of interest:* none

**Abstract**

Cancer immunotherapy, focused on harnessing and empowering the immune system against tumours, has transformed modern oncology. One of the most promising avenues in development involves using genetically engineered T-cells to target cancer antigens *via* specific T-cell receptors (TCRs). TCRs have a naturally low affinity towards cancer-associated antigens, and therefore show scope for improvement. Here we describe approaches to procure TCRs with enhanced affinity and specificity towards cancer, using protein engineering or selection of natural TCRs from unadulterated repertoires. In particular, we discuss novel methods facilitating the targeting of tumour-specific mutations. Finally, we provide a prospective outlook on the potential development of novel, off-the-shelf immunotherapies by leveraging recent advances in genome editing.

Abstract: 111 words (100-120)

Main text: 1866 (<2,000)

Objects: (up to 4) – 1 table, 3 figures (+graphical abstract)

References: 53 (~50) – and around 50% are from 2016&2017

**Highlights (3-5, 85 characters each):**

- T-cell receptors (TCRs) can be used to re-direct patients' immune system to cancer
- Directed evolution can enhance TCR affinity towards cancer antigens
- Affinity-enhanced TCRs can be used in gene transfer or as soluble molecules
- TCR targeting of somatic mutations offers personalised, safe and specific therapy
- Modern genome engineering offers promise of new improved immunotherapies

*Cancer patient*　　*Humanised mouse model*　　*Healthy donor*

**Protein engineering of**

**cancer-specific T-cell receptors**

*Gene transfer*

*Soluble bispecific molecules*

**Re-directing patient's T-cells to cancer**

*Legut and Sewell, graphical abstract*

## Introduction

Conventional cytotoxic CD8[+] T-cells recognise short peptide antigens, derived from degradation of intracellular proteins and presented by molecular cradles called the major histocompatibility complex (MHC, also known as human leukocyte antigen, HLA) class I at the cell surface (reviewed in [1]). This recognition allows T-cells to scan the intracellular proteome for anomalies and destroy cells expressing foreign, pathogen-derived proteins. Recognition of the highly variegated MHC-associated peptide cargo is possible thanks to generation of diverse αβ T-cell receptors (TCRs) by somatic gene rearrangement process that has potential to theoretically generate ~$10^{18}$ different receptors in human [2]. Immature T-cells are then selected in the thymus so that only those with TCRs that weakly engage self MHC molecules are allowed to enter the periphery. Cells that bear inept TCRs "die by neglect" while those that recognise self peptides strongly, and have capacity to induce autoimmunity, are culled [3] Thus, the TCRs of T-cells that populate the periphery should not be self-reactive but have potential to bind foreign peptides with relatively high affinity. This central tolerance mechanism restricts the TCR pool with anticancer specificity to predominantly weak affinity receptors [4] because the majority of cancer antigens, with a notable exception of neoantigens stemming from mutated proteins, are derived from over- or aberrantly expressed self-proteins [5] (**Figure 1**). The challenge that this presents to anti-tumour T-cells is further amplified because successful tumours exploit a variety of systems that are designed to protect against excessive T-cell activity in the periphery [6]. Neutralisation of peripheral tolerance mechanisms via the application of immune checkpoint inhibitors has shown great promise in cancer treatment but is associated with concomitant autoimmune toxicities [7]. More targeted approaches in current development aim to adoptively transfer cancer-reactive T-cells. Adoptive T-cell therapy originally involved transfer of expanded tumour infiltrating lymphocytes [8] but has been extended to include autologous T-cells engineered *ex vivo* to express well-defined, cancer-specific receptors. The genetic redirection of T-cells to cancer can be achieved by using antibody-like chimeric antigen receptors (CARs) targeting surface-expressed proteins (which became the first gene therapy approved by the FDA [9]), or via conventional TCRs which can scan the intracellular proteome presented as peptide-MHC complexes. Here we discuss the recent developments in procurement of the optimal TCRs for cancer immunotherapy and cutting-edge technologies that enable high throughput, in-depth assessment of potentially therapeutic TCRs.

## The critical importance of TCR affinity

The first-in-human attempt to re-direct patient T-cells to cancer was conducted in 2006 by Rosenberg and colleagues and used the DMF4 TCR that targets a peptide from a melanocyte differentiation antigen highly expressed in melanoma [10]. While the results of that clinical trial were encouraging in terms of safety and feasibility, only a relatively small fraction of patients experienced an objective response (**Table 1**). The clinical response was improved in the follow up trial which made use of another *natural* TCR targeting the same epitope as DMF4 but selected by screening of hundreds of T-cell clones for TCRs exhibiting substantially higher sensitivity [11,12]. These two trials therefore demonstrated the importance of T-cell sensitivity to antigen, a property known to be critically dependent on TCR affinity/half-life [13]. As natural anti-cancer TCRs are of low affinity, several strategies have been devised to generate TCRs with optimal affinity as described below.

## Directed evolution can create super-high affinity TCRs

The first robust method for affinity maturation of TCRs involved displaying a degenerate library of TCRs on the surface of M13 bacteriophage, followed by several rounds of increasingly stringent selection using immobilised cognate peptide-MHC complexes. This directed evolution approach, routinely applied to antibody production, could increase the TCR-peptide-MHC affinity by over a million-fold, through introduction of multiple mutations in the short hairpin loops, termed complementarity determining regions (CDR), that comprise the antigen binding site [14]. Yeast display, aided by computation modelling, has also been used to generate TCRs with enhanced binding affinity and/or stability [15–17].

Affinity maturation can enhance the natural affinity of anti-tumour TCRs (dissociation constant $K_D$ range 10-100 μM [3]) by over a million-fold ($K_D$ ~10 pM [14]). However, TCRs with affinities that are higher than the very strongest natural TCRs ($K_D$ <0.1 μM) can activate T-cells irrespective of the cognate peptide [13,18,19] (**Figure 2A**). Additionally, engineered TCRs circumvent the rigours of thymic selection so that even slight alterations to TCR sequence may lead to unexpected cross-reactivities with antigens other than the cognate peptide-MHC. Such cross-reactivities can result in fatal adverse events [20–22]. Despite these caveats, TCRs with pM affinity towards cancer antigens could be used therapeutically as soluble molecules instead of in TCR gene-modified T-cells, without compromising the peptide specificity (**Figure 2B**). These super-high affinity TCRs can efficiently label cancer cells presenting endogenously processed peptide antigens (as few as 5 copies per cell [23]) and, when linked to an anti-CD3 antibody fragment, are capable of re-directing polyclonal populations of T-cells to kill cancer [24]. TCR-anti-CD3 antibody fusion proteins, termed ImmTAC™ (immune-mobilising monoclonal TCRs against cancer), have been developed by Immunocore (Abingdon, UK) and are being tested in six clinical trials, either as a single agent or in combination with checkpoint inhibitors (clinicaltrials.gov identifiers: NCT02889861, NCT01211262, NCT03070392, NCT01209676, NCT02570308, NCT02535078). A detailed description of how to manufacture super-high affinity TCR-anti-CD3 antibody fusion proteins has recently been published [25].

**Bypassing thymic selection yields highly sensitive TCRs**

Procurement of TCRs from T-cell populations that have not been selected against self antigens, such as HLA-transgenic murine models, provides a further way of generating high affinity cancer-specific receptors [11]. An extension of this methodology that avoids any potential immunogenicity of murine TCRs when transferred to human patients was proposed by Blankenstein and colleagues, whereby mice were humanised to express both a given HLA allele and the human *tcr* locus [26]. The lack of human antigens in these mice prevents deletion of high affinity human-reactive TCRs in the thymus. Thymic deletion can also be bypassed by using HLA-mismatched donors to generate allo-TCRs specific for a given peptide-MHC [27]. Allogenic TCRs are sensitive enough to target antigens expressed at a very low copy number that cannot be targeted by antibody-based therapies [28]. However, it is crucial to ensure that TCRs procured from allogeneic HLA donors are truly peptide-specific rather that recognising allo-HLA irrespective of the peptide cargo. Finally, enhanced affinity TCRs can be procured by antigen-driven differentiation of TCR-α transduced haematopoietic progenitor cells (HPCs) *in vitro*. Since HPCs undergo natural TCR-β rearrangement, the resulting TCRs do not contain any mutations in germline-encoded CDR loops, and non-germline encoded CDR3s can differ in length compared to parental TCR, making this approach potentially safer and more versatile than directed evolution of TCR proteins [29].

**TCRs targeting tumour neoantigens are sensitive and specific – but at a price**

Accumulation of somatic mutations is a hallmark feature of cancer. If non-synonymous mutations occur within protein fragments that can be displayed by MHC molecules, these potentially

immunogenic epitopes are termed "neoantigens" [30]. MHC-presented neoantigens offer an attractive target for immunotherapy as they are non-self, highly specific to cancer cells and circumvent thymic selection. T-cell responses against mutated antigens, but not the unmutated counterpart, can be sporadically detected in patients, and exploited to induce cancer regression [31]. Neoantigen-reactive T-cells can be identified non-invasively in peripheral blood of cancer patients using programmed death (PD)-1 expression as a biomarker prior to testing antigen specificity using mutations identified by high-throughput tumour exome and transcriptome sequencing [32]. Neoantigen-specific TCRs identified in this way can be subsequently used for personalised therapy. While targeting even a single point mutation with a specific TCR may be sufficient to eradicate established tumours, the particular mutation must be uniformly expressed by heterogeneous tumour cell populations and be essential for cancer cell fitness in order to avoid selection of escape variants [33]. Since cancer immunoediting ensures poor immunogenicity of potential driver mutations, at least at the early stages of cancer formation, endogenous T-cell pools may neglect the most therapeutically relevant mutations [34]. This problem can be circumvented by using HLA-matched healthy donors to procure TCRs against neoantigens that have escaped detection during the process of immunoediting [35].

Given the heterogenous composition of tumours and potential for immunoevasion when targeting only a single point mutation, it would seem optimal, although cost and labour-intensive, to target several neoantigens simultaneously, using an array of different TCRs. Emerging technologies may make targeting neoantigens more streamlined and applicable to larger cohorts of patients. Advances in high-throughput sequencing now enable rapid, non-invasive determination of mutations within the neoplastic exome [36]. Several cutting-edge methods have also been devised to infer the TCR specificity. We and others developed high-throughput methods for identification of cognate peptide ligands of TCRs of interest, using combinatorial peptide libraries [37,38] or yeast-display libraries of peptide-MHC [39]. Additionally, TCRs specific for predicted, patient-derived neoantigens can be identified and selected in a massively parallel way, by using DNA-barcoded peptide-MHC multimers, thus enabling screening of >1,000 putative peptide antigens in one sample [40]. This powerful technology can be further combined with single-cell transcriptomics [41], leading to rapid and streamlined identification of candidate TCRs. Finally, the most promising, neoantigen-specific TCRs can be introduced into patient-derived T-cells using a transposon/transposase system, offering a safer and cheaper alternative to currently used γ-retroviral/lentiviral vectors [42].

**Perspectives – the brave new world of genome editing and synthetic biology**

The ideal therapeutic T-cell should: (i) efficiently traffic to the tumour site; (ii) overcome the immunosuppressive microenvironment; (iii) successfully target all, potentially heterogeneous, tumour cells; (iv) be inert to healthy tissues; and, (v) be available as an off-the-shelf product that can be administered to patients regardless of their HLA allelic composition (**Figure 3**). While this may seem like wishful thinking, recent advances in synthetic biology and genome editing offer a very real potential to sculpt T-cells to fit a given therapeutic purpose. Tailoring T-cells to exact therapeutic needs can be achieved using artificial gene circuits, such as recently developed synthetic Notch receptors [43], engineered to release a selected transcription factor upon antigen binding to drive a bespoke transcription programme within the tumour [44]. T-cells can also be engineered to express two antigen receptors, with the second one becoming expressed only after productive antigen recognition by the first so as to limit the possible damage to healthy tissue [45]. However, the improved specificity of such dual recognition also amplifies the risk of cancer evasion. An off-the-shelf T-cell product would ideally be devoid of endogenous HLA to reduce the speed of rejection by the recipient immune system and express an antigen receptor that recognises cancer irrespective of

patient HLA type [46]. Removal of donor HLA and TCR is easily achievable by using programmable nucleases, and thus engineered allogenic T-cell products transduced with anti-CD19 CAR have recently been used in clinic [47]. Non-HLA restricted TCRs provide an alternative to CARs; in this respect tumour-specific γδ TCRs may prove more applicable than the conventional αβ TCR options that are currently being explored in the clinic. γδ TCRs can target a broad range of cancers but not healthy tissue - however, little is still known about possible ligands for these TCRs (reviewed in [48]). We have recently shown that using gene editing to remove endogenous αβ TCRs greatly enhances the anticancer activity of donor T-cells simultaneously transduced with γδ TCRs [49], and thus expect non-HLA restricted TCRs to be worthy of further clinical investigation.

**Conflict of interest statement**

Nothing declared.

**References and recommended reading**

Papers of particular interest, published within the period of review, have been highlighted as:

> • of special interest

> •• of outstanding interest

**Acknowledgements**

**References**

1. Attaf M, Legut M, Cole DK, Sewell AK: **The T cell antigen receptor: The Swiss Army knife of the immune system**. *Clin Exp Immunol* 2015, doi:10.1111/cei.12622.

2. Sewell AK: **Why must T cells be cross-reactive?** *Nat Rev Immunol* 2012, **12**:669–677.

3. Xing Y, Hogquist KA: **T-Cell Tolerance: Central and Peripheral**. *Cold Spring Harb Perspect Biol* 2012, **4**:a006957–a006957.

4. Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, Price DA, Gao GF, Sewell AK, Jakobsen BK: **Human TCR-Binding Affinity is Governed by MHC Class Restriction**. *J Immunol* 2007, **178**:5727–5734.

5. Pritchard AL, Hastie ML, Neller M, Gorman JJ, Schmidt CW, Hayward NK: **Exploration of peptides bound to MHC class I molecules in melanoma**. *Pigment Cell Melanoma Res* 2015, **28**:281–294.

6. Mapara MY, Sykes M: **Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance**. *J Clin Oncol* 2004, **22**:1136–1151.

7.  Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, et al.: **Immune-related adverse events with immune checkpoint blockade: a comprehensive review**. *Eur J Cancer* 2016, **54**:139–148.

8.  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al.: **Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy**. *Clin Cancer Res* 2011, **17**:4550–4557.

9.  Ruella M, Kenderian SS: **Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf**. *BioDrugs* 2017, **31**:473–481.

10. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al.: **Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes**. *Science* 2006, **314**:126–129.

11. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, et al.: **Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen**. *Blood* 2009, **114**:535–546.

12. Johnson LA, Heemskerk B, Powell DJ, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA: **Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes**. *J Immunol* 2006, **177**:6548–6559.

13. Tan MP, Gerry AB, Brewer JE, Melchiori L, Bridgeman JS, Bennett AD, Pumphrey NJ, Jakobsen BK, Price DA, Ladell K, et al.: **T cell receptor binding affinity governs the functional profile of cancer-specific CD8 $^+$ T cells: TCR affinity governs T cell function**. *Clin Exp Immunol* 2015, **180**:255–270.

14. Li Y, Moysey R, Molloy PE, Vuidepot A-L, Mahon T, Baston E, Dunn S, Liddy N, Jacob J, Jakobsen BK, et al.: **Directed evolution of human T-cell receptors with picomolar affinities by phage display**. *Nat Biotechnol* 2005, **23**:349–354.

15. • Harris DT, Wang N, Riley TP, Anderson SD, Singh NK, Procko E, Baker BM, Kranz DM: **Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex**. *J Biol Chem* 2016, **291**:24566–24578.

This paper describes a combination of yeast-display mediated directed evolution of T-cell receptors with computational approaches to generate enhanced-affinity receptors.

16. Harris DT, Singh NK, Cai Q, Smith SN, Vander Kooi CW, Procko E, Kranz DM, Baker BM: **An Engineered Switch in T Cell Receptor Specificity Leads to an Unusual but Functional Binding Geometry**. *Structure* 2016, **24**:1142–1154.

17. Sharma P, Kranz DM: **Subtle changes at the variable domain interface of the T-cell receptor can strongly increase affinity**. *J Biol Chem* 2017, doi:10.1074/jbc.M117.814152.

18. Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LYL, Li Y, Molloy PE, Dunn SM, Jakobsen BK, et al.: **High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines**. *J Immunol* 2007, **179**:5845–5854.

19. • Tan MP, Dolton GM, Gerry AB, Brewer JE, Bennett AD, Pumphrey NJ, Jakobsen BK, Sewell AK: **Human leucocyte antigen class I-redirected anti-tumour CD4 [+] T cells require a higher T cell receptor binding affinity for optimal activity than CD8 [+] T cells: Anti-tumour HLA I-restricted CD4 [+] T cells**. *Clin Exp Immunol* 2017, **187**:124–137.

The authors conducted a direct comparison of several clinically relevant engineered T-cell receptors, spanning a range of affinities from wild-type to super-high affinity ($K_D$ µM-pM), and the impact on TCR affinity on the specificity and effector function of different T-cell subsets.

20. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, et al.: **Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy:** *J Immunother* 2013, **36**:133–151.

21. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, et al.: **Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma**. *Blood* 2013, **122**:863–871.

22. • Raman MCC, Rizkallah PJ, Simmons R, Donnellan Z, Dukes J, Bossi G, Le Provost GS, Todorov P, Baston E, Hickman E, et al.: **Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy**. *Sci Rep* 2016, **6**.

This paper provides structural evidence of unexpected cross-reactivity of affinity-enhanced T-cell receptor during a clinical trial which was terminated due to fatal adverse events.

23. McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, et al.: **Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors**. *Cancer Immunol Immunother* 2013, **62**:773–785.

24. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, et al.: **Monoclonal TCR-redirected tumor cell killing**. *Nat Med* 2012, **18**:980–987.

25. • Zhang H, Zhang J, Chen L, Weng Z, Tian Y, Zhao H, Li Y, Chen L, Liang Z, Zheng H, et al.: **Targeting naturally occurring epitope variants of hepatitis C virus with high-affinity T-cell receptors**. *J Gen Virol* 2017, **98**:374–384.

The authors provide a detailed description of how to generate super-high affinity T-cell receptors coupled with anti-CD3 antibody for efficient re-direction of polyclonal T-cell populations to cells expressing cognate antigen..

26. Obenaus M, Leitão C, Leisegang M, Chen X, Gavvovidis I, van der Bruggen P, Uckert W, Schendel DJ, Blankenstein T: **Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice**. *Nat Biotechnol* 2015, **33**:402–407.

27. Jahn L, Hombrink P, Hagedoorn RS, Kester MGD, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, et al.: **TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1**. *Blood* 2017, **129**:1284–1295.

28. • Jahn L, van der Steen DM, Hagedoorn RS, Hombrink P, Kester MGD, Schoonakker MP, de Ridder D, van Veelen PA, Falkenburg JHF, Heemskerk MHM: **Generation of CD20-specific TCRs for TCR gene therapy of CD20[low] B-cell malignancies insusceptible to CD20-targeting antibodies**. *Oncotarget* 2016, **7**.

Heemskerk and colleagues derive highly sensitive anticancer TCRs from allogeneic donors, to show that TCRs targeting a given antigen have an advantage over antibodies targeting the same antigen.

29. •• Schmitt TM, Aggen DH, Ishida-Tsubota K, Ochsenreither S, Kranz DM, Greenberg PD: **Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro**. *Nat Biotechnol* 2017, **35**:1188–1195.

This paper leverages the natural process of T-cell differentiation conducted *in vitro*, outside of thymic selection, to generate enhanced affitity TCRs with potentially improved safety profile than enhanced affitity TCRs generated by directed evolution.

30. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW: **Cancer Genome Landscapes**. *Science* 2013, **339**:1546–1558.

31. Tran E, Turcotte S, Gros A, Robbins PF, Lu Y-C, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al.: **Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer**. *Science* 2014, **344**:641–645.

32. • Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al.: **Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients**. *Nat Med* 2016, **22**:433–438.

Gros et al show that potentially therapeutic TCRs can be identified in patients' peripheral blood, without the need of conducting a tumour biopsy and extensive *ex vivo* culturing.

33. • Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, et al.: **Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation**. *Clin Cancer Res* 2016, **22**:2734–2743.

This paper shows that while targeting a single point mutation in cancer can elicit initial regression, it drives selection of cancer cells which are negative for the targeted mutation, highlighting the important consideration of tumour immunoevasion.

34. • Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, de Prisco N, Ideker T, Hildebrand WH, Font-Burgada J, et al.: **MHC-I Genotype Restricts the Oncogenic Mutational Landscape**. *Cell* 2017, **171**:1272–1283.e15.

This is the first paper to provide direct evidence for the immunoediting of mutations that commonly drive cancer development and progression.

35. •• Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Boschen M-L, Lund-Johansen F, Olweus J, et al.: **Targeting of cancer neoantigens with donor-derived T cell receptor repertoires**. *Science* 2016, **352**:1337–1341.

Schumacher and colleagues show that healthy donors may be an efficient source of neoantigen-specific TCRs to target cancer-specific mutations that are neglected by the endogenous TCR pool of cancer patients.

36. Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, et al.: **Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors**. *Nat Commun* 2017, **8**.

37.     Wooldridge L, Ekeruche-Makinde J, van den Berg HA, Skowera A, Miles JJ, Tan MP, Dolton G, Clement M, Llewellyn-Lacey S, Price DA, et al.: **A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides**. *J Biol Chem* 2012, **287**:1168–1177.

38.     • Szomolay B, Liu J, Brown PE, Miles JJ, Clement M, Llewellyn-Lacey S, Dolton G, Ekeruche-Makinde J, Lissina A, Schauenburg AJ, et al.: **Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors**. *Immunol Cell Biol* 2016, **94**:573–582.

This paper outlines the combinatorial peptide screening approach, combined with computational analysis of bespoke protein databases, to identify cognate peptide ligands of clinically relevant TCRs.

39.     • Gee MH, Han A, Lofgren SM, Beausang JF, Mendoza JL, Birnbaum ME, Bethune MT, Fischer S, Yang X, Gomez-Eerland R, et al.: **Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes**. *Cell* 2017, doi:10.1016/j.cell.2017.11.043.

This paper outlines the yeast-display approach to identify cognate peptide ligands of clinically relevant TCRs.

40.     •• Bentzen AK, Marquard AM, Lyngaa R, Saini SK, Ramskov S, Donia M, Such L, Furness AJS, McGranahan N, Rosenthal R, et al.: **Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes**. *Nat Biotechnol* 2016, **34**:1037–1045.

The authors describe a high throuput approach to study the TCR repertoire in cancer patients, looking simultaneously at hundreds of potential epitopes, including patient-specific neoantigens.

41.     • Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK, Swerdlow H, Satija R, Smibert P: **Simultaneous epitope and transcriptome measurement in single cells**. *Nat Methods* 2017, **14**:865–868.

Smibert and colleagues demonstrate that single cell technologies can be extended to measure the surface proteome and transcriptome simultaneously, in a variety of immunological contexts.

42.     Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, Cooper LJ, Rosenberg SA: **Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System**. *Mol Ther* 2016, **24**:1078–1089.

43.     Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, Lim WA: **Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors**. *Cell* 2016, **164**:780–791.

44.     •• Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA, Lim WA: **Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors**. *Cell* 2016, **167**:419–432.e16.

Roybal et al describe a robust synthetic biology approach which allows tailoring T-cells for a very specific and bespoke therapeutic function performed directly at the tumour site.

45.     Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA: **Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits**. *Cell* 2016, **164**:770–779.

46.     Levine BL, Miskin J, Wonnacott K, Keir C: **Global Manufacturing of CAR T Cell Therapy**. *Mol Ther - Methods Clin Dev* 2017, **4**:92–101.

47.    • Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, et al.: **Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells**. *Sci Transl Med* 2017, **9**:eaaj2013.

The paper describes a successful clinical trial involving first-in-human administration of allogeneic T-cells engineered to express a CD19 specific CAR in conjunction with disruption of endogenous genes that could mediate graft versus host disease.

48.    Legut M, Cole DK, Sewell AK: **The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy**. *Cell Mol Immunol* 2015, doi:10.1038/cmi.2015.28.

49.    • Legut M, Dolton G, Mian AA, Ottmann O, Sewell A: **CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells**. *Blood* 2017, doi:10.1182/blood-2017-05-787598.

This paper demonstrates that genome engineering of primary T-cells to disrupt their endogenous TCRs substantially increases the anticancer reactivity of the engineered cells, especially when transduced with non-MHC restricted TCRs.

50.    Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al.: **Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1**. *J Clin Oncol* 2011, **29**:917–924.

51.    Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al.: **A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response**. *Clin Cancer Res* 2015, **21**:1019–1027.

52.    Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, et al.: **NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma**. *Nat Med* 2015, **21**:914–921.

53.    Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan D-AN, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, et al.: **T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis**. *Mol Ther* 2011, **19**:620–626.

54.    Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, et al.: **Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer**. *Clin Cancer Res* 2015, **21**:2268–2277.

**Table 1 Completed clinical trials utilising TCR-transduced T-cells for cancer immunotherapy**. Target refers to the protein from which the cognate peptide is derived (presented by HLA-A2, unless indicated otherwise) while the response rate indicates the number of patients experiencing objective clinical response out of all the evaluated patients. † denotes TCRs of murine origin; * presented by HLA-A1; ‡ presented by HLA-A24. MART, melanoma-associated antigen recognised by T-cells; NY-ESO, New York esophageal squamous cell carcinoma; CEA, carcinoembryonic antigen; MAGE, melanoma antigen gene.

| Target | TCR | Cancer | Response | Adverse effects | Reference |
|--------|-----|--------|----------|-----------------|-----------|
| MART-1 | Wild type | Metastatic melanoma | 2/17 | None | [10] |
| MART-1 | Wild type | Metastatic melanoma | 6/20 | Grade 3 | [11] |
| gp100 | Wild type† | Metastatic melanoma | 3/16 | Grade 3 | [11] |
| NY-ESO-1 | Affinity enhanced | Metastatic melanoma, synovial cell carcinoma | 9/17 | None | [50] |
| NY-ESO-1 | Affinity enhanced | Metastatic melanoma, synovial cell carcinoma | 22/38 | None | [51] |
| NY-ESO-1 | Affinity enhanced | Multiple myeloma | 18/20 | Grade 3 | [52] |
| CEA | Affinity enhanced† | Metastatic colorectal cancer | 1/3 | Grade 3 | [53] |
| MAGE-A3 | Affinity enhanced† | Metastatic melanoma/ synovial cell carcinoma/ oesophageal cancer | 5/9 | Fatality | [20] |
| MAGE-A3* | Affinity enhanced | Metastatic melanoma/ multiple myeloma | 0/2 | Fatality | [21] |
| MAGE-A4‡ | Wild type† | oesophageal cancer | 0/10 | None | [54] |

**Figure legends:**

**Figure 1. Natural anticancer responses consist of T-cells recognising short peptide antigens derived from aberrantly-expressed or mutated proteins.** T-cells scan the intracellular proteome, presented as short peptides bound to MHC class I at the cell surface, using their hypervariable TCRs. The process of thymic selection prevents autoimmunity by culling T-cells bearing TCRs with high affinity towards peptides derived from self-proteins. Since many tumour-associated antigens are derived from self-proteins which are over- or aberrantly expressed (in particular, proteins expressed predominantly in immunologically privileged sites such as testes or developing foetus give rise to tumour antigens), thymic selection limits the pool of TCRs specific for these antigens to weak affinity, sub-optimal receptors. Thymic selection has little impact on TCRs specific for cancer-specific peptides arising from non-synonymous somatic mutations, as these are essentially foreign, highly personalised, antigens.

**Figure 2. The affinity of TCRs towards cognate peptide-MHC can be enhanced – but requires tailoring to a particular application**. (**A**) TCRs targeting cancer in context of peptide-MHC class I can be used for genetic re-direction of patient CD8 cytotoxic and CD4 helper T-cells. However, unmodified TCRs have a relatively weak affinity towards self/cancer-antigens – which may be sufficient to re-direct cytotoxic T-cells (which use CD8 co-receptor to enhance TCR binding to peptide-MHC-I) but not helper T-cells. As a result, CD4 T-cells require TCRs with higher affinity than CD8 T-cells to target cancer antigens via MHC-I without loss of specificity. Enhancing the TCR affinity to sub-nanomolar levels generally correlates with non-specific recognition of MHC molecules, when transduced into primary T-cells. Based on [17]. (**B**) TCRs with sub-nanomolar affinity towards their cognate antigens can be used as soluble molecules and are capable of binding to cancer cells with long half-lives. These super-high affinity TCRs can be covalently linked to single chain variable fragments (scFv) of an antibody (UCHT1) specific for CD3 molecule. Since CD3 is a component of the TCR, these bispecific reagents are capable of re-directing patient polyclonal T-cells to target cancer. Based on [23].

**Figure 3. Hallmarks of an optimal cellular product for adoptive cell transfer.** An optimal T-cell product can be generated by combination of gene knock-ins (for instance, delivered via a lentiviral vector) and knock-outs (transiently delivered in a form of Cas9 complexed with gRNAs). While Cas9 system can be easily multiplexed to target multiple genes at the same time, the amount of exogenous DNA that can be knocked in is limited by vector packaging constraints and cellular fitness considerations. Therefore, it may be advantageous to use an optimal T-cell subset for starting material, exhibiting the desired phenotype, cytokines and chemokine receptors. An alternative approach would involve using mutant Cas9 to activate endogenous gene expression. Finally, a safe off-the-shelf T-cell product should not express endogenous TCRs which can drive graft versus host disease, or endogenous MHC-I molecules which can lead to donor cell rejection. An optimal off-the-shelf T-cell product should target cancer, but not essential tissues, *via* a non-MHC restricted receptor to allow recognition in all patients.

# T-cells

low affinity
TCR

low affinity
TCR

high affinity
TCR

*MHC-I + self-peptide*

*MHC-I + aberrantly expressed self-peptide*

*MHC-I + mutated self-peptide*

| peptide processing and loading onto MHC-I |
|---|

| proteasomal protein degradation |
|---|

| transcription, translation |
|---|

normal
expression

aberrant
expression

non-synonymous
mutation

**A**

TCR affinity ($K_D$)

Cytotoxic CD8⁺ T-cells | Helper CD4⁺ T-cells

1 µM

1 nM

1 pM

weak response | no response

strong response | weak response

loss of specificity | strong response

loss of specificity | loss of specificity

**B**

Super high affinity, cancer-specific TCR

Anti-CD3 scFv

T-cell

Peptide-MHC

CD3-TCR complex (*not cancer specific*)

**Lysis**

cancer cell

*Legut and Sewell, Figure 2*

Targeting

Trafficking

Persistence

Safety

Microenvironment

TCR+CD3

chemokine receptors

IL-2

IL-15

transduced DNA

CD28

suicide switches

Cas9

endogenous DNA

immunomodulatory cytokines

PD-1

MHC-I

*Legut and Sewell, Figure 3*